Pharmacists in Knoxville, IA Accepting Medicare
6 Pharmacists found. Showing 1 - 6
 Paul Herrmann Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 809 W Rock Island St, Knoxville, IA 50138 Phone: 641-842-2512 |
 Daphne Pearson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 318 N Lincoln St, Knoxville, IA 50138 Phone: 641-828-7312 Fax: 641-828-6303 |
Susan Switzer, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1002 S Lincoln St, Knoxville, IA 50138 Phone: 641-842-5661 Fax: 641-842-1491 |
Troy Padellford, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1002 S Lincoln St, Knoxville, IA 50138 Phone: 641-842-1433 |
Anna Elizabeth Fischer, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 809 W Rock Island St, Knoxville, IA 50138 Phone: 641-842-2512 |
Katie Cope, PHARMD, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 318 N Lincoln St, Knoxville, IA 50138 Phone: 641-828-7312 |
News Archive
Hemodynamic Therapeutics' HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint
Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound ("HTI-101"), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension.
Scientists perform metagenomic analysis of bacterial immune system for personalized oral health care
The human body is home to a complex ecosystem of microbes increasingly recognized as having a critical role in both health and disease.
GlySure awarded three U.S. patents for proprietary calibration technique, sensor membrane
GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, announced today that it has been awarded three U.S. patents covering the company's core proprietary calibration technique and sensor membrane.
Eli Lilly to appeal against U.S. District Court ruling in Strattera patent litigation
Eli Lilly and Company today announced that the U.S. District Court for the District of New Jersey has ruled against the company in its patent litigation for Strattera. In the case of Eli Lilly and Company v. Actavis Elizabeth LLC, et al, the court ruled that Lilly's '590 patent, or method-of-use patent, for Strattera is invalid. The patent had been set to expire in May of 2017.
Alzheimer's disease often detected late due to lack of screening finds report
Alzheimer's disease and dementia is fast becoming an important presence. A new survey released as part of the Alzheimer's Association's 2019 Alzheimer's Disease Facts and Figures report has revealed that there is often a delay in seeking help for dementia and associated cognitive decline.
› Verified 3 days ago
Counselors
Dentists
Pharmacists
Clinical Social Workers
Psychologists
Occupational Therapists